Immunotherapy for cancer: How tumor recurrence can be avoided
In recent years, immunotherapy has emerged as a promising alternative in the fight against cancer. However, there are many drawbacks, as tumors often recur in patients after a period of remission. An international research team at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), the Berlin Institute of Health (BIH), and the Charité has now elucidated one mechanism that underlies tumor recurrence and how to prevent it. These findings could help find more suitable targets for therapy in the future. The study has now been presented in the most recent issue of the Journal of Experimental Medicine.